Home › Steatotic Liver Disease › Maryland
Steatotic Liver Disease clinical trials in Maryland
8 studies for Steatotic Liver Disease are looking for participants at sites in Maryland.
Cities in Maryland
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Mercy Medical Center - Baltimore, Baltimore
- Capital Digestive Care - Chevy Chase, Chevy Chase
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Baltimore
- Akero Clinical Study Site, Bethesda
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Sep 21, 2026 · NCT06528314A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- Mid-Atlantic GI Research, Greenbelt
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 9, 2026 · NCT07288138A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Baltimore
- 89bio Clinical Study Site, Glen Burnie
- 89bio Clinical Study Site, Greenbelt
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 3, 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Baltimore
- 89bio Clinical Study Site, Glen Burnie
- 89bio Clinical Study Site, Greenbelt
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Sep 3, 2026 · NCT06318169Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2Healthy volunteers welcome
Ages 18 to 100 · All sexes · Updated Aug 10, 2026 · NCT03884075Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 1Healthy volunteers welcome
Ages 21 to 65 · All sexes · Updated Jul 20, 2026 · NCT04781322A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, Baltimore
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Jul 8, 2026 · NCT06920043From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.